Sainan Li

Sainan Li

Auto-generated profile, based on publicly available information

Sainan Li

Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2015 in Marine Drugs
Verified
Journal Article
Open access
PDF file
JLJingjing Li
Jingjing Li
FWFan Wang
Fan Wang
YXYujing Xia
Yujing Xia
WDWeiqi Dai
Weiqi Dai
KCKan Chen
Kan Chen
CGChuanyong Guo
Chuanyong Guo
Background: Hepatic ischemia reperfusion (IR) is an important issue in complex liver resection and liver transplantation. The aim of the present study was to determine the protective effect of astaxanthin (ASX), an antioxidant, on hepatic IR injury via the reactive oxygen species/mitogen-activated protein kinase (ROS/MAPK) pathway. Methods: Mice were randomized into a sham, IR, ASX or IR + ASX group. The mice received ASX at different doses (30 mg/kg or 60 mg/kg) for 14 days. Serum and tissue samples at 2 h, 8 h and 24 h after abdominal surgery were collected to assess alanine aminotransferase (ALT), aspartate aminotransferase (AST), inflammation factors, ROS, and key proteins in the MAPK family. Results: ASX reduced the release of ROS and cytokines leading to inhibition of apoptosis and autophagy via down-regulation of the activated phosphorylation of related proteins in the MAPK family, such as P38 MAPK, JNK and ERK in this model of hepatic IR injury. Conclusion: Apoptosis and autophagy caused by hepatic IR injury were inhibited by ASX following a reduction in the release of ROS and inflammatory cytokines, and the relationship between the two may be associated with the inactivation of the MAPK family.

24 September 2015 in Marine Drugs
Verified
Journal Article
Open access
PDF file
JLJingjing Li
Jingjing Li
WDWeiqi Dai
Weiqi Dai
YXYujing Xia
Yujing Xia
KCKan Chen
Kan Chen
SLSainan Li
Sainan Li
CGChuanyong Guo
Chuanyong Guo
Hepatocellular carcinoma (HCC) is a malignant tumor that can cause systemic invasion; however, the exact etiology and molecular mechanism are unknown. Astaxanthin (ASX), a powerful antioxidant, has efficient anti-oxidant, anti-inflammatory, and other activities, and has great research prospects in cancer therapy. We selected the human hepatoma cell lines, LM3 and SMMC-7721, to study the anti-tumor effect and related mechanisms of ASX. The cell lines were treated with different concentrations of ASX, and its solvent DMSO as a control, for different time periods and the results were determined using CCK8, qRT-PCR, WB, apoptotic staining, and flow cytometry. ASX induced significant apoptosis of HCC cells, and its effect may have been caused by NF-κB p65 and Wnt/β-catenin down-regulation via negative activation of PI3K/Akt and ERK. Antitumor research on ASX has provided us with a potential therapy for patients with hepatomas.

1 July 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
XLXiya Lu
Xiya Lu
TLTong Liu
Tong Liu
KCKan Chen
Kan Chen
YXYujing Xia
Yujing Xia
WDWeiqi Dai
Weiqi Dai
CGChuanyong Guo
Chuanyong Guo

1 December 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
LWLiwei Wu
Liwei Wu
CWChengfen Wang
Chengfen Wang
JLJingjing Li
Jingjing Li
SLSainan Li
Sainan Li
JFJiao Feng
Jiao Feng
CGChuanyong Guo
Chuanyong Guo

1 May 2016 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
KCKan Chen
Kan Chen
JLJingjing Li
Jingjing Li
SLSainan Li
Sainan Li
JFJiao Feng
Jiao Feng
LWLiwei Wu
Liwei Wu
CGChuanyong Guo
Chuanyong Guo